Teva fights for re-listing of inhaler patents at US appeals court
Oral arguments heard in case between Teva and generics maker Amneal over inhaler patents | Teva says district court and Amneal asked court to ‘slice apart new drug application’.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
1 August 2024 Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed.
1 August 2024 Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed.
1 August 2024 Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed.